Trial · NCT07272902
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
NCT07272902, Not applicable, Recruiting, Nova Scotia Health Authority
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication. Trials, record NCT07272902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07272902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
- NCT number
- NCT07272902
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 84 participants, estimated
- Lead sponsor
- Nova Scotia Health Authority
- Conditions
- Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFPEF), Rate Control, Rhythm Control
- Interventions
- Catheter Ablation for Atrial Fibrillation, Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)
- First posted
- 2025-12-09
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of Trial Conduct | 12 months after randomization | Recruitment rate (patients recruited per center per month) and crossover rate (percentage of participants switching study arms). Feasibility will be defined as ≥0.7 patients enrolled per center per month and ≤10% crossover. |
| Secondary | Composite of Cardiovascular Mortality and Heart Failure Hospitalization | Up to 12 months post-randomization | Time to first event of cardiovascular death (due to MI, sudden cardiac death, HF, stroke, CV procedures, CV bleeding, or other CV cause) or hospitalization for heart failure (admission \>24h, ED visit, or unscheduled IV diuretic administration). |
| Secondary | All-Cause Mortality | Up to 12 months | Death from any cause |
| Secondary | Cardiovascular Hospitalizations and ED Visits (Non-HF) | Up to 12 months | Number of hospitalizations or emergency department visits for other cardiovascular causes, including atrial fibrillation. |
| Secondary | Quality of Life: EQ-5D (Euroquol 5D Questionnaire) | Baseline, 12 months | EQ5D Will include responses from the Euroquol 5D questionnaire |
| Secondary | Quality of Life: AFEQT (Atrial Fibrillation Effect on Quality of Life) Questionnaire | Baseline, 12 months | AFEQT- Atrial Fibrillation Effect on Quality of Life Questionnaire (Scored 0-100, 0 is complete disability, 100 is no disability) |
| Secondary | Quality of life- KCCQ-12 (Kansas City Cardiomyopathy Questionnaire-12) | Baseline, 12 months | KCCQ-12- Kansas City Cardiomyopathy Questionnaire-12 (0-100, 0 is very poor, 100 is excellent) |
| Secondary | Atrial Fibrillation Burden | Baseline, 3, 6, and 12 months | Proportion of time in atrial fibrillation as measured by Holter monitoring and symptom-triggered ECG recordings |
| Secondary | Change in NT-proBNP levels | Baseline, 12 months | Change in plasma NT-proBNP levels from baseline to follow-up |
| Secondary | Change in Left Ventricular Ejection Fraction (LVEF) | Baseline, 12 months | Change in LVEF as measured by echocardiography |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07272902
GET https://conductscience.org/api/trials/v1/NCT07272902/registered